HIF3A (HIF3 alpha) Antibody (YA7891)

Cat. No.: HY-P88207: Data Sheet User Guide for Antibodies
FAQs
Technical Support

HIF3A (HIF3 alpha) Antibody (YA7891) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HIF3A (HIF3 alpha).

For research use only. We do not sell to patients.

Size	Price	Stock
20 μL		Ask For Quote & Lead Time
50 μL		Ask For Quote & Lead Time
100 μL		Ask For Quote & Lead Time

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

HIF3A (HIF3 alpha) Antibody (YA7891) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HIF3A (HIF3 alpha).

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 72.3 kDa

Species Reactivity

Human

SwissProt ID

Q9Y2N7

Immunogen

Human recombinant protein fragment corresponding to amino acids 355-669 of human HIF3A produced in E.coli.

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:150-500

Sensitivity	Endogenous	Purity	Affinity purified
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG1

Appearance

Liquid

Formulation

Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Acts as a transcriptional regulator in adaptive response to low oxygen tension. Acts as a regulator of hypoxia-inducible gene expression (PubMed:11573933, PubMed:16126907, PubMed:19694616, PubMed:20416395, PubMed:21069422). Functions as an inhibitor of angiogenesis in hypoxic cells of the cornea. Plays a role in the development of the cardiorespiratory system. May also be involved in apoptosis (By similarity)|Attenuates the ability of transcription factor HIF1A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation. Also inhibits hypoxia-inducible ARNT-mediated gene expression|Attenuates the ability of transcription factor HIF1A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation|Attenuates the ability of transcription factor HIF1A and EPAS1/HIF2A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation (PubMed:16126907, PubMed:17998805, PubMed:19694616, PubMed:20416395). May act as a tumor suppressor and inhibits malignant cell transformation (PubMed:17998805)|Attenuates the ability of transcription factor HIF1A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation

Subcellular Localization：Nucleus,Cytoplasm,Nucleus speckle,Mitochondrion

Expression：
Tissue_Specificity: Expressed in vascular cells (at protein level) (PubMed:21069422). Expressed in kidney (PubMed:11573933, PubMed:19694616). Expressed in lung epithelial cells (PubMed:16775626). Expressed in endothelial cells (venous and arterial cells from umbilical cord and aortic endothelial cells) and in vascular smooth muscle cells (aorta) (PubMed:21069422). Strongly expressed in the heart, placenta, and skeletal muscle, whereas a weak expression profile was found in the lung, liver, and kidney (PubMed:12538644). Expressed weakly in cell renal cell carcinoma (CC-RCC) compared to normal renal cells (PubMed:16126907). Expression is down-regulated in numerous kidney tumor cells compared to non tumor kidney tissues (PubMed:16126907). Isoform 2 is expressed in heart, placenta, lung, liver, skeletal muscle and pancreas and in numerous cancer cell lines (PubMed:20416395). Isoform 3 and isoform 4 are weakly expressed in heart, placenta, lung, liver, skeletal muscle and pancreas (PubMed:20416395). Isoform 4 is expressed in fetal tissues, such as heart, brain, thymus, lung, liver, skeletal kidney and spleen (PubMed:20416395). Isoform 3 is weakly expressed in fetal tissues, such as liver and kidney (PubMed:20416395)
Induction: Up-regulated by hypoxia (at protein level) (PubMed:16775626). Induced by hypoxia (PubMed:16775626). Isoform 2, isoform 3, isoform 4 and isoform 5 are up-regulated by hypoxia in a HIF1A- and EPAS1/HIF2A-dependent manner (PubMed:19694616, PubMed:20416395, PubMed:21069422). Isoform 4 is down-regulated by hypoxia and up-regulated upon restoring normoxia in embryonic kidney cells (PubMed:16126907)

Isoforms & Post-Translational Modification：Q9Y2N7 has 7 isomers: Q9Y2N7-1: 72433 Da (predicted); Q9Y2N7-2: 72405 Da (predicted); Q9Y2N7-3: 68964 Da (predicted); Q9Y2N7-4: 39962 Da (predicted); Q9Y2N7-5: 66142 Da (predicted); Q9Y2N7-6: 62393 Da (predicted); Q9Y2N7-7: 64359 Da (predicted).
In normoxia, hydroxylated on Pro-492 in the oxygen-dependent degradation domain (ODD) by prolyl hydroxylase(s) (PHD)丨Ubiquitinated; ubiquitination occurs in a VHL- and oxygen-dependent pathway and subsequently targeted for proteasomal degradation

Subunit：Isoform 2 interacts (via ODD domain) with VHL (via beta domain) (PubMed:12538644)

Synonyms

bHLHe17; HIF-3A; HIF3-alpha-1; IPAS; MOP7; PASD7

Documentation

User Guide for Antibodies (1077 KB)